|
1
|
Kurman RJ and Shih IeM: Molecular
pathogenesis and extraovarian origin of epithelial ovarian cancer -
shifting the paradigm. Hum Pathol. 42:918–931. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Crispens MA, Bodurka D, Deavers M, et al:
Response and survival in patients with progressive or recurrent
serous ovarian tumors of low malignant potential. Obstet Gynecol.
99:3–10. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Gershenson DM, Sun CC, Bodurka D, et al:
Recurrent low-grade serous ovarian carcinoma is relatively
chemoresistant. Gynecol Oncol. 114:48–52. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Schmeler KM, Sun CC, Bodurka DC, et al:
Neoadjuvant chemotherapy for low-grade serous carcinoma of the
ovary or peritoneum. Gynecol Oncol. 108:510–514. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Shvartsman HS, Sun CC, Bodurka DC, et al:
Comparison of the clinical behavior of newly diagnosed stages II–IV
low-grade serous carcinoma of the ovary with that of serous ovarian
tumors of low malignant potential that recur as low-grade serous
carcinoma. Gynecol Oncol. 105:625–629. 2007.PubMed/NCBI
|
|
6
|
Singer G, Oldt R III, Cohen Y, et al:
Mutations in BRAF and KRAS characterize the development of
low-grade ovarian serous carcinoma. J Natl Cancer Inst. 95:484–486.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Mayr D, Hirschmann A, Lohrs U and Diebold
J: KRAS and BRAF mutations in ovarian tumors: a comprehensive study
of invasive carcinomas, borderline tumors and extraovarian
implants. Gynecol Oncol. 103:883–887. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sieben NL, Macropoulos P, Roemen GM, et
al: In ovarian neoplasms, BRAF, but not KRAS, mutations are
restricted to low-grade serous tumors. J Pathol. 202:336–340. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Jones S, Wang TL, Kurman RJ, et al:
Low-grade serous carcinomas of the ovary contain very few point
mutations. J Pathol. 226:413–420. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bollag G, Hirth P, Tsai J, et al: Clinical
efficacy of a RAF inhibitor needs broad target blockade in
BRAF-mutant melanoma. Nature. 467:596–599. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Nakayama N, Nakayama K, Yeasmin S, et al:
KRAS or BRAF mutation status is s useful predictor of sensitivity
to MEK inhibition in ovarian cancer. Br J Cancer. 99:2020–2028.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Pohl G, Ho CL, Kurman RJ, et al:
Inactivation of the mitogen-activated protein kinase pathway as a
potential target-based therapy in ovarian serous tumors with KRAS
or BRAF mutations. Cancer Res. 65:1994–2000. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Didelot A, Le Corre D, Luscan A, et al:
Competitive allele specific TaqMan PCR for KRAS, BRAF and EGFR
mutation detection in clinical formalin fixed paraffin embedded
samples. Exp Mol Pathol. 92:275–280. 2012. View Article : Google Scholar
|
|
14
|
Capper D, Preusser M, Habel A, et al:
Assessment of BRAF V600E mutation status by immunohistochemistry
with a mutation-specific monoclonal antibody. Acta Neuropathol.
122:11–19. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Capper D, Berghoff AS, Magerle M, et al:
Immunohistochemical testing of BRAF V600E status in 1,120 tumor
tissue samples of patients with brain metastases. Acta Neuropathol.
123:223–233. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sasaki H, Shimizu S, Tani Y, et al:
Usefulness of immunohistochemistry for the detection of the BRAF
V600E mutation in Japanese lung adenocarcinoma. Lung Cancer.
82:51–54. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Bösmüller H, Fischer A, Pham DL, et al:
Detection of the BRAF V600E mutation in serous ovarian tumors: a
comparative analysis of immunohistochemistry with a
mutation-specific monoclonal antibody and allele-specific PCR. Hum
Pathol. 44:329–335. 2013.PubMed/NCBI
|
|
18
|
Bustin SA, Benes V, Garson JA, et al: The
MIQE guidelines: minimum information for publication of
quantitative real-time PCR experiments. Clin Chem. 55:611–622.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lamy A, Blanchard F, Le Pessort F, et al:
Metastatic colorectal cancer KRAS genotyping in routine practice:
results and pitfalls. Mod Pathol. 24:1090–1100. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Anderson S, Bloom KJ, Vallera DU, et al:
Multisite analytic performance studies of a real-time polymerase
chain reaction assay for the detection of BRAF V600E mutations in
formalin-fixed, paraffin-embedded tissue specimens of malignant
melanoma. Arch Pathol Lab Med. 136:1385–1391. 2012. View Article : Google Scholar
|
|
21
|
Yancovitz M, Litterman A, Yoon J, et al:
Intra- and inter-tumor heterogeneity of BRAF(V600E) mutations in
primary and metastatic melanoma. PLos One. 7:e293362012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Huang T, Zhuge J and Zhang WW: Sensitive
detection of BRAF V600E mutation by Amplification Refractory
Mutation System (ARMS)-PCR. Biomark Res. 1:32013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Brevet M, Arcita M and Ladanyi M:
Assessment of EGFR mutation status in lung adenocarcinoma by
immunohistochemistry using antibodies specific to the two major
forms of mutant EGFR. J Mol Diagn. 12:169–176. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Sahm F, Capper D, Meyer J, et al:
Immunohistochemical analysis of 1844 human epithelial and
haemotopoietic tumours and sarcomas for IDH1R132H mutation.
Histopathology. 58:1167–1172. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Raab S: The cost-effectiveness of
immunohistochemistry. Arch Pathol Lab Med. 124:1185–1191.
2000.PubMed/NCBI
|
|
26
|
Rossle M, Sigg M, Ruschoff JH, et al:
Ultra-deep sequencing confirms immunohistochemistry as a highly
sensitive and specific method for detecting BRAF V600E mutations in
colorectal carcinoma. Virchows Arch. 463:623–631. 2013. View Article : Google Scholar
|
|
27
|
Grisham RN, Iyer G, Garg K, et al: BRAF
mutation is associated with early stage disease and improved
outcome in patients with low-grade serous ovarian cancer. Cancer.
119:548–554. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wong KK, Tsang YT, Deavers MT, et al: BRAF
mutation is rare in advanced-stage low-grade ovarian serous
carcinomas. Am J Pathol. 177:1611–1617. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Farley J, Brady WE, Vathipadiekal V, et
al: Selumetinib in women with recurrent low-grade serous carcinoma
of the ovary or peritoneum: an open-label, single-arm, phase 2
study. Lancet Oncol. 14:134–140. 2013. View Article : Google Scholar : PubMed/NCBI
|
